Home page

Fully human Fab synthetic library

Xichang Bio currently has a storage capacity of 10. ¹¹ A fully human Fab synthetic library; the ultimate goal is to establish a hundred-billion‑member fully human Fab synthetic library, dedicated to helping pharmaceutical and diagnostic‑reagent companies develop high‑affinity, highly specific antibody candidates.

Service Advantages

● Optimal germline sequence: suitable for phage display, high expression levels, and good drug‑like properties.

● Randomization strategy: Trimer primers, diverse CDR3 lengths, and varied amino acid distributions

● Optimal reservoir capacity: Reservoir capacity close to 10 ¹¹ Good diversity, reduced ineffective screening.

● The broadest range of applications: validated across dozens of targets, suitable for diverse target types, with affinities reaching the pM level.

Service Content

Serial number	Main steps	Content	Cycle	Delivery Result
1	Antigen preparation	The customer provides 2 mg of antigen for screening and preliminary identification.
2	Phage library screening (fully human Fab synthetic library)	1.3–4 rounds of selection 2. Candidate Clone Identification 3. ELISA ranking 4. Sequencing and Sequence Analysis	4–8 weeks	Up to 40 sequences will be provided in batches—20 in the first batch and 20 in the second—for full‑length antibody expression, followed by activity validation for the customer.
3	Expression and purification of full-length antibodies	Convert the antibodies obtained through phage display into their full-length IgG1 form or the customer‑specified full‑length format, express them, and purify them by affinity chromatography.	2-3 weeks	Each sequence contains up to 1 mg of protein (concentration > 1 mg/mL; 1-step purification: SEC > 95%, SDS-PAGE > 95%).
4	Total cycle	6–11 weeks

Service Cases

Case Study of Screening Using Phage Display Technology for Synthetic Libraries

Name	Commercial Name	Format	Target	Company	Clinical Indication	Status	Phage Display Type
Atezolizumab	Tecentriq	Humanized IgG1	PD-L1	Roche, Genentech	Cancers, Melanoma, Solid Tumors, hepatocellular carcinoma, others	Market	Human Library (Fab`-zip synthetic single-framework)
Brodalumab	Kyntheum, Siliq	Human IgG2	IL-17RA	Valeant Pharmaceuticals; LEO Pharma	Plaque psoriasis	Market	MorphoSyś HuCAL
Brodalumab	Kyntheum, Siliq	Human IgG2	IL-17RA	Valeant Pharmaceuticals; LEO Pharma	Plaque psoriasis	Market	MorphoSyś HuCAL
Faricimab	Vabysmo	Human/Humanized IgG1	VEGF-A, Ang-2	Roche	Macular degeneration	Approved	Synthetic human Fab library
Guselkumab	TREMFYA™	Human IgG1	IL23A	Morphosys (Germany); Morphosys and Janssen Biotech (USA)	Psoriatic arthritis, psoriasis, palmoplantar pustulosis, others	Approved	MorphoSyś HuCAL
Tafasitamab	Monjuvi	Humanized IgG1/2	CD19	Xencor	Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia	Approved	MorphoSyś HuCAL
Tebentafusp	KIMMTRAK	Human TCR-scFv	gp100, CD3	Immunocore	Metastatic uveal melanoma	Approved	Synthetic TCR-phage library
Tralokinumab	Adbry™ (USA) Adtralza® (EU)	Human IgG4	IL-13	LEO Pharma	Atopic dermatitis, asthma	Approved	Synthetic human scFv library
Tralokinumab	Adbry™ (USA) Adtralza® (EU)	Human IgG4	IL-13	LEO Pharma	Atopic dermatitis, asthma	Approved	Synthetic human scFv library
Felzartamab	N/A	IgG1-lambda	CD38	HI-Bio	MM	Phase II-III	Synthetic Fab HuCAL GOLD (MorphoSyś)
Anetumab ravtansine	N/A	Human IgG1-lambda – DM4	MSLN	Bayer	Solid tumors, MPM	Phase II	MorphoSyś HuCAL GOLD
Carlumab	N/A	Human IgG1-kappa	CCL2	Gilead Sciences	Prostate cancer	Phase I-II	MorphoSyś HuCAL GOLD